VNDA
NASDAQ · Biotechnology
Vanda Pharmaceuticals Inc
$7.00
-0.10 (-1.41%)
Open$7.10
Previous Close$7.10
Day High$7.17
Day Low$6.98
52W High$9.94
52W Low$3.81
Volume—
Avg Volume1.30M
Market Cap377.70M
P/E Ratio—
EPS$-3.74
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+120.7% upside
Current
$7.00
$7.00
Target
$15.45
$15.45
$11.33
$15.45 avg
$18.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 197.87M | 208.92M | 122.09M |
| Net Income | -201,870,029 | -191,830,879 | 12.67M |
| Profit Margin | -102.0% | -96.9% | 10.4% |
| EBITDA | -120,529,567 | -120,898,625 | 21.61M |
| Free Cash Flow | — | — | 20.08M |
| Rev Growth | -5.3% | -5.3% | +22.8% |
| Debt/Equity | 0.02 | 0.02 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |